Analysts/Institutional Investor Meet/Con. Call Updates

August 06, 2026 To To The Secretary The Secretary National Stock Exchange of India Limited BSE Limited Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (East) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Trading Symbol: DIVISLAB Scrip Code: 532488 Dear Sir / Madam, Sub: Transcript of earnings conference call held on August 01, 2026 Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 We hereby submit the transcript of the earnings conference call for the quarter ended June 30, 2026, held on August 01, 2026, at 14.00 hrs. (IST). The transcript is also available on the website of the Company i.e. www.divislabs.com , under the Investors Relations section. This is for your information and records. Thanking You, Yours faithfully, For Divi's Laboratories Limited M. Satish Choudhury Company Secretary & Compliance Officer “Divi’s Laboratories Limited Q1 FY27 Earnings Conference Call” August 01, 2026 MANAGEMENT: DR. KIRAN S. DIVI – WHOLE-TIME DIRECTOR AND CHIEF EXECUTIVE OFFICER – DIVI’S LABORATORIES LIMITED MS. NILIMA PRASAD DIVI –WHOLE-TIME DIRECTOR (COMMERCIAL) – DIVI’S LABORATORIES LIMITED MR. VENKATESA PERUMALLU PASUMARTHY – CHIEF FINANCIAL OFFICER – DIVI’S LABORATORIES LIMITED MR. M. SATISH CHOUDHURY – COMPANY SECRETARY AND CHIEF INVESTOR RELATIONS OFFICER – DIVI’S LABORATORIES LIMITED Page 1 of 17 Divi’s Laboratories Limited August 01, 2026 Moderator: Ladies and gentlemen, good day, and welcome to the Earnings Conference Call of Divi's Laboratories Limited for Q1 FY27. As a reminder, all participants will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touch-tone phone. Please note that this conference has been recorded. I now hand the conference over to Mr. M. Satish Choudhury. Thank you, and over to you, sir. M. Satish Choudhury: Good afternoon to all of you. I am M. Satish Choudhury, Company Secretary and Chief Investor Relations Officer of Divi's Laboratories Limited. I welcome you to the earnings call of the Divi’s Laboratories Limited for the first quarter of FY27. From Divi's Labs, we have with us today, Dr. Kiran S. Divi, Whole-Time Director & CEO; Ms. Nilima Prasad Divi, Whole-Time Director (Commercial); and Mr. Venkatesa Perumallu Pasumarthy, Chief Financial Officer. During the day, our Board has approved unaudited financial results for the quarter ended June 30, 2026, and we have released the same to the stock exchanges as well as updated in our website. Please note that this conference call is being recorded, and a transcript of the same will be made available on the website of the Company. Please also note that the audio of the con-call is copyright material of Divi’s Laboratories Limited and cannot be copied, rebroadcasted or attributed in press or media without specific and written consent. Let me draw your attention to the fact that on this call, our discussion will include certain forward-looking statements, which are predictions, projections or other estimates about future events. These estimates reflect management's current expectations of the future performance of the Company. Please note that these estimates involve several risks and uncertainties that could cause our actual results to differ materially from what is expressed or implied. Divi's Labs or its officials does not undertake any obligation to publicly update any forward-looking statement, whether as a result of future events or otherwise. Now I hand over the conference to Dr. Kiran Divi for opening remarks. Over to you, sir. Dr. Kiran S. Divi: Good afternoon everyone, and welcome to the Divi’s Laboratories earnings call for the first quarter of the financial year 2026-27. Thank you for joining us today. I will begin with an update on the business and the key operational developments during the quarter. Our focus continues to be on execution, manufacturing reliability, disciplined capital deployment and strengthening the capabilities required to support long-term customer programmes. Beginning with our Generic business, volumes remained stable during the quarter, while pricing continues to reflect competitive market conditions across products and geographies. Overall, the Page 2 of 17 Divi’s Laboratories Limited August 01, 2026 business remained resilient based on our ability to manufacture certain key starting materials and intermediates in-house which continues to strengthen our supply assurance and operational efficiency. This year also marks 20 years of Divi’s in the nutraceutical segment - a journey that began with just two products has grown into a portfolio of over 100 offerings across human health, animal health and dietary supplements in multiple forms today. As we look ahead, we are actively expanding in both capabilities and capacities to meet the demand of a rapidly evolving global market. Within Custom Synthesis, projects actively continued across all diverse portfolio of customer programmes covering multiple therapeutic areas and stages of development. We are supporting customers across clinical development, validation and commercial supply preparations, with manufacturing activities are aligned to individual regulatory and filing requirements. Likewise, the three major capex programmes are nearing completion and validations are going on. As our projects progress, we remain focused on timely execution while continuing to build the infrastructure and technical capabilities required to support future commercial requirements. Peptides remain a strategic area of investment for the Company. Customer programmes continue to progress across multiple phases of development during the quarter, while qualification and validation activities for several peptides fragments are expected to advance over the coming quarters. Alongside capacity expansion in both solid-phase and liquid-phase peptide synthesis, we continue to strengthen the process development, analytical and manufacturing capabilities required for increasingly complex peptide chemistry. Our objective is to establish a scalable and reliable manufacturing platform capable of supporting a broad range of customer requirements while maintaining the highest standard of quality, compliance and operational excellence. On the manufacturing front, Unit 3 continues to assume a large role within our production network. The facility is supporting our backward integration strategy through selected pre- chemistry operations, while enabling the phased transfer of manufacturing activities from our existing facilities. This enhances supply assurance for critical intermediaries, improving network flexibility and supports more efficient capacity utilization across our manufacturing operations. The transfer programme continues to be executed in line with qualification timelines, customer commitments, product demand and overall manufacturing planning. Technology development also remains an important area of execution during the quarter. Progress continues across initiatives involving continuous flow chemistry, biocatalysis and advanced automation within the manufacturing operations. These technologies are contributing to improved process safety enhanced product producibility, reduce process variability and more sustainable manufacturing routes for complex chemistries. We also continue to implement process intensification initiatives across selected products to improve productivity and support efficient commercial scale manufacturing. Across our manufacturing network, ongoing investments in green chemistry, energy efficiency and continued process improvement remain an integral part of our long-term operational strategy. Page 3 of 17 Divi’s Laboratories Limited August 01, 2026 Collectively, these initiatives strengthen our technical capabilities and enhance our ability to dev [Showing first 8,000 characters — download PDF for full document]